Huaren Pharmaceutical Co Ltd (300110) - Total Assets
Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) holds total assets worth CN¥2.79 Billion CNY (≈ $407.92 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Huaren Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.
Huaren Pharmaceutical Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Huaren Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Huaren Pharmaceutical Co Ltd (300110) shareholders funds for net asset value and shareholders' equity analysis.
Huaren Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Huaren Pharmaceutical Co Ltd's total assets of CN¥2.79 Billion consist of 36.8% current assets and 63.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.1% |
| Accounts Receivable | CN¥484.14 Million | 17.9% |
| Inventory | CN¥241.51 Million | 8.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥287.30 Million | 10.6% |
| Goodwill | CN¥207.89 Million | 7.7% |
Asset Composition Trend (2007–2025)
This chart illustrates how Huaren Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Huaren Pharmaceutical Co Ltd (300110) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Huaren Pharmaceutical Co Ltd's current assets represent 36.8% of total assets in 2025, a decrease from 44.9% in 2007.
- Cash Position: Cash and equivalents constituted 5.1% of total assets in 2025, up from 3.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 4.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 17.9% of total assets.
Huaren Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Huaren Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Huaren Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.82 | 0.72 | 1.33 |
| Quick Ratio | 0.64 | 0.55 | 1.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-242.62 Million | CN¥-454.22 Million | CN¥694.21 Million |
Huaren Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Huaren Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -21.2% |
| Total Assets | CN¥2.70 Billion |
| Market Capitalization | $463.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Huaren Pharmaceutical Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Huaren Pharmaceutical Co Ltd's assets decreased by 21.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Huaren Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total assets of Huaren Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.70 Billion ≈ $395.39 Million |
-21.18% |
| 2024-12-31 | CN¥3.43 Billion ≈ $501.64 Million |
-33.64% |
| 2023-12-31 | CN¥5.17 Billion ≈ $755.90 Million |
+0.06% |
| 2022-12-31 | CN¥5.16 Billion ≈ $755.44 Million |
-8.49% |
| 2021-12-31 | CN¥5.64 Billion ≈ $825.53 Million |
+65.17% |
| 2020-12-31 | CN¥3.42 Billion ≈ $499.80 Million |
+26.02% |
| 2019-12-31 | CN¥2.71 Billion ≈ $396.60 Million |
-13.97% |
| 2018-12-31 | CN¥3.15 Billion ≈ $461.00 Million |
+9.12% |
| 2017-12-31 | CN¥2.89 Billion ≈ $422.47 Million |
+5.95% |
| 2016-12-31 | CN¥2.72 Billion ≈ $398.74 Million |
-0.87% |
| 2015-12-31 | CN¥2.75 Billion ≈ $402.23 Million |
+4.85% |
| 2014-12-31 | CN¥2.62 Billion ≈ $383.62 Million |
+10.76% |
| 2013-12-31 | CN¥2.37 Billion ≈ $346.35 Million |
+32.60% |
| 2012-12-31 | CN¥1.78 Billion ≈ $261.19 Million |
+43.08% |
| 2011-12-31 | CN¥1.25 Billion ≈ $182.55 Million |
+8.31% |
| 2010-12-31 | CN¥1.15 Billion ≈ $168.54 Million |
+81.15% |
| 2009-12-31 | CN¥635.78 Million ≈ $93.04 Million |
+25.32% |
| 2008-12-31 | CN¥507.33 Million ≈ $74.24 Million |
+40.08% |
| 2007-12-31 | CN¥362.18 Million ≈ $53.00 Million |
-- |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more